Deciphera Pharmaceuticals (DCPH) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DCPH Hot Sheet
Join SI Premium – FREE
Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q3 EPS of ($1.13), $0.17 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $15.5 million versus the consensus estimate of $7.05 million.
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Moderna shares rise ahead of Thursday earnings report
- Apple shares slip amid guidance for tightening margins, slowing services growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
